Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Front Behav Neurosci ; 14: 581296, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33312120

RESUMEN

A role of the gut microbiota in psychiatric disorders is supported by a growing body of literature. The effects of a probiotic mixture of four bacterial strains were studied in two models of anxiety and depression, naturally stress-sensitive Fischer rats and Long Evans rats subjected to maternal deprivation. Rats chronically received either the probiotic mixture (1.109 CFU/day) or the vehicle. Anxiety- and depressive-like behaviors were evaluated in several tests. Brain monoamine levels and gut RNA expression of tight junction proteins (Tjp) and inflammatory markers were quantified. The gut microbiota was analyzed in feces by 16S rRNA gene sequencing. Untargeted metabolite analysis reflecting primary metabolism was performed in the cecal content and in serum. Fischer rats treated with the probiotic mixture manifested a decrease in anxiety-like behaviors, in the immobility time in the forced swimming test, as well as in levels of dopamine and its major metabolites, and those of serotonin metabolites in the hippocampus and striatum. In maternally deprived Long Evans rats treated with the probiotic mixture, the number of entries into the central area in the open-field test was increased, reflecting an anxiolytic effect. The probiotic mixture increased Tjp1 and decreased Ifnγ mRNA levels in the ileum of maternally deprived rats. In both models, probiotic supplementation changed the proportions of several Operational Taxonomic Units (OTU) in the gut microbiota, and the levels of certain cecal and serum metabolites were correlated with behavioral changes. Chronic administration of the tested probiotic mixture can therefore beneficially affect anxiety- and depressive-like behaviors in rats, possibly owing to changes in the levels of certain metabolites, such as 21-deoxycortisol, and changes in brain monoamines.

2.
Neuropsychiatr Dis Treat ; 14: 1821-1829, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30034237

RESUMEN

OBJECTIVE: The medicinal plants Rhodiola rosea L. (rhodiola, golden root) and Crocus sativus L. (saffron) have been shown separately to induce significant effects in depression. The objective of this study was to assess a fixed combination of rhodiola and saffron in mild-moderate depression. METHODS: In this observational study conducted with general practitioners (GPs), 45 adults (aged 18-85 years) suffering from mild or moderate depression (International Statistical Classification of Diseases and Related Health Problems 10th Revision definition) and reaching a score on the Hamilton Rating Scale for Depression of 8-18 were supplemented with a combination of rhodiola and saffron extracts (one tablet, 154 mg of rhodiola and 15 mg of saffron; recommended dose two tablets per day for 6 weeks). RESULTS: After 6 weeks (D42) of supplementation, Hamilton Rating Scale for Depression scores (primary outcome) decreased significantly by 58%±28.5% (from 13.6±2.3 at D0 to 5.6±3.8 at D42, P<0.0001; n=41). Score improvement was reported in 85.4% of patients. A significant drop in both Hospital Anxiety and Depression Scale anxiety and depression scores was also observed at D42, the decrease being significant from 2 weeks of supplementation. At the end of the study, both GPs and patients deemed there was a significant improvement in depression (Clinical Global Impression - improvement and Patient Global Impression of Change). Safety was excellent, and no serious adverse effects were recorded. CONCLUSION: Results of this observational study performed in primary care suggest that the combination of rhodiola and saffron tested could be useful for the management of mild-moderate depression and improve depressive and anxiety symptoms. A double-blind placebo-controlled study is needed to confirm these results.

3.
BMC Complement Altern Med ; 17(1): 433, 2017 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-28854909

RESUMEN

BACKGROUND: Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study. METHODS: Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months. RESULTS: Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated. CONCLUSIONS: Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.


Asunto(s)
Combinación de Medicamentos , Magnesio/administración & dosificación , Trastornos Migrañosos/prevención & control , Extractos Vegetales/administración & dosificación , Tanacetum parthenium/química , Ubiquinona/análogos & derivados , Adolescente , Adulto , Anciano , Suplementos Dietéticos/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Calidad de Vida , Ubiquinona/administración & dosificación , Adulto Joven
4.
Muscle Nerve ; 45(4): 567-77, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22431091

RESUMEN

INTRODUCTION: The effects of locomotor training (LT) on skeletal muscle after peripheral nerve injury and acetylcholinesterase deficiency are not well documented. METHODS: We determined the effects of LT on mouse soleus muscle performance after sciatic nerve transection with excision (full and permanent denervation), nerve transection (partial functional reinnervation), nerve crush (full denervation with full functional reinnervation), and acetylcholinesterase deficiency (alteration in neuromuscular junction functioning). RESULTS: We found no significant effect of LT on the recovery of soleus muscle weight, maximal force in response to muscle stimulation, and fatigue resistance after nerve transection with or without excision. However, LT significantly increased soleus muscle fatigue resistance after nerve crush and acetylcholinesterase deficiency. Moreover, hindlimb immobilization significantly aggravated the deficit in soleus muscle maximal force production and atrophy after nerve crush. CONCLUSIONS: LT is beneficial, and reduced muscle use is detrimental for intrinsic muscle performance in the context of disturbed nerve-muscle communication.


Asunto(s)
Terapia por Ejercicio , Locomoción/fisiología , Neuronas Motoras/fisiología , Músculo Esquelético/inervación , Músculo Esquelético/fisiopatología , Enfermedades Neuromusculares/fisiopatología , Acetilcolinesterasa/deficiencia , Animales , Atrofia , Estimulación Eléctrica , Suspensión Trasera/fisiología , Técnicas In Vitro , Contracción Isométrica , Masculino , Ratones , Neuronas Motoras/patología , Contracción Muscular/fisiología , Desnervación Muscular , Fatiga Muscular/fisiología , Músculo Esquelético/patología , Compresión Nerviosa , Enfermedades Neuromusculares/patología , Tamaño de los Órganos , Resistencia Física/fisiología , Nervio Ciático/patología
5.
Am J Pathol ; 180(5): 2040-55, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22449950

RESUMEN

Congenital peripheral nerve hyperexcitability (PNH) is usually associated with impaired function of voltage-gated K(+) channels (VGKCs) in neuromyotonia and demyelination in peripheral neuropathies. Schwartz-Jampel syndrome (SJS) is a form of PNH that is due to hypomorphic mutations of perlecan, the major proteoglycan of basement membranes. Schwann cell basement membrane and its cell receptors are critical for the myelination and organization of the nodes of Ranvier. We therefore studied a mouse model of SJS to determine whether a role for perlecan in these functions could account for PNH when perlecan is lacking. We revealed a role for perlecan in the longitudinal elongation and organization of myelinating Schwann cells because perlecan-deficient mice had shorter internodes, more numerous Schmidt-Lanterman incisures, and increased amounts of internodal fast VGKCs. Perlecan-deficient mice did not display demyelination events along the nerve trunk but developed dysmyelination of the preterminal segment associated with denervation processes at the neuromuscular junction. Investigating the excitability properties of the peripheral nerve suggested a persistent axonal depolarization during nerve firing in vitro, most likely due to defective K(+) homeostasis, and excluded the nerve trunk as the original site for PNH. Altogether, our data shed light on perlecan function by revealing critical roles in Schwann cell physiology and suggest that PNH in SJS originates distally from synergistic actions of peripheral nerve and neuromuscular junction changes.


Asunto(s)
Axones/fisiología , Proteoglicanos de Heparán Sulfato/fisiología , Osteocondrodisplasias/patología , Células de Schwann/fisiología , Potenciales de Acción/fisiología , Envejecimiento/fisiología , Animales , Membrana Basal/metabolismo , Enfermedades Desmielinizantes/etiología , Modelos Animales de Enfermedad , Estimulación Eléctrica/métodos , Proteoglicanos de Heparán Sulfato/deficiencia , Proteoglicanos de Heparán Sulfato/genética , Canal de Potasio Kv.1.1/biosíntesis , Ratones , Ratones Mutantes , Microscopía Electrónica , Mutación , Vaina de Mielina/fisiología , Vaina de Mielina/ultraestructura , Unión Neuromuscular/fisiopatología , Osteocondrodisplasias/complicaciones , Osteocondrodisplasias/fisiopatología , Nódulos de Ranvier/metabolismo , Nódulos de Ranvier/ultraestructura , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Células de Schwann/metabolismo , Nervio Ciático/fisiopatología , Nervio Ciático/ultraestructura
6.
Muscle Nerve ; 40(1): 55-61, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19367640

RESUMEN

Schwartz-Jampel syndrome (SJS) is an autosomal-recessive condition characterized by muscle stiffness and chondrodysplasia. It is due to loss-of-function hypomorphic mutations in the HSPG2 gene that encodes for perlecan, a proteoglycan secreted into the basement membrane. The origin of muscle stiffness in SJS is debated. To resolve this issue, we performed an electrophysiological investigation of an SJS mouse model with a missense mutation in the HSPG2 gene. Compound muscle action potential amplitudes, distal motor latencies, repetitive nerve stimulation tests, and sensory nerve conduction velocities of SJS mice were normal. On electromyography (EMG), neuromyotonic discharges, that is, bursts of motor unit action potentials firing at high rates (120-300 HZ), were constantly observed in SJS mice in all muscles, except in the diaphragm. Neuromyotonic discharges were not influenced by general anesthesia and disappeared with curare administration. They persisted after complete motor nerve section, terminating only with Wallerian degeneration. These results demonstrate that perlecan deficiency in SJS provokes a neuromyotonic syndrome. The findings further suggest a distal axonal localization of the generator of neuromyotonic discharges. SJS should now be considered as an inherited disorder with peripheral nerve hyperexcitability.


Asunto(s)
Fibras Musculares Esqueléticas/fisiología , Osteocondrodisplasias/patología , Osteocondrodisplasias/fisiopatología , Nervios Periféricos/fisiopatología , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Animales , Fenómenos Biofísicos , Curare/farmacología , Modelos Animales de Enfermedad , Estimulación Eléctrica/métodos , Electromiografía/métodos , Proteoglicanos de Heparán Sulfato/deficiencia , Proteoglicanos de Heparán Sulfato/genética , Ratones , Ratones Transgénicos , Mutación Missense/genética , Conducción Nerviosa/efectos de los fármacos , Conducción Nerviosa/genética , Conducción Nerviosa/fisiología , Fármacos Neuromusculares no Despolarizantes/farmacología , Osteocondrodisplasias/genética , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología
7.
Hum Mol Genet ; 17(20): 3166-79, 2008 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-18647752

RESUMEN

Schwartz-Jampel syndrome (SJS) is a recessive neuromyotonia with chondrodysplasia. It results from hypomorphic mutations of the gene encoding perlecan, leading to a decrease in the levels of this heparan sulphate proteoglycan in basement membranes (BMs). It has been suggested that SJS neuromyotonia may result from endplate acetylcholinesterase (AChE) deficiency, but this hypothesis has never been investigated in vivo due to the lack of an animal model for neuromyotonia. We used homologous recombination to generate a knock-in mouse strain with one missense substitution, corresponding to a human familial SJS mutation (p.C1532Y), in the perlecan gene. We derived two lines, one with the p.C1532Y substitution alone and one with p.C1532Y and the selectable marker Neo, to down-regulate perlecan gene activity and to test for a dosage effect of perlecan in mammals. These two lines mimicked SJS neuromyotonia with spontaneous activity on electromyogramm (EMG). An inverse correlation between disease severity and perlecan secretion in the BMs was observed at the macroscopic and microscopic levels, consistent with a dosage effect. Endplate AChE levels were low in both lines, due to synaptic perlecan deficiency rather than major myofibre or neuromuscular junction disorganization. Studies of muscle contractile properties showed muscle fatigability at low frequencies of nerve stimulation and suggested that partial endplate AChE deficiency might contribute to SJS muscle stiffness by potentiating muscle force. However, physiological endplate AChE deficiency was not associated with spontaneous activity at rest on EMG in the diaphragm, suggesting that additional changes are required to generate such activity characteristic of SJS.


Asunto(s)
Acetilcolinesterasa/deficiencia , Acetilcolinesterasa/genética , Síndrome de Isaacs/enzimología , Síndrome de Isaacs/genética , Placa Motora/enzimología , Osteocondrodisplasias/enzimología , Osteocondrodisplasias/genética , Alelos , Animales , Modelos Animales de Enfermedad , Electromiografía , Femenino , Dosificación de Gen , Proteoglicanos de Heparán Sulfato/deficiencia , Proteoglicanos de Heparán Sulfato/genética , Humanos , Síndrome de Isaacs/fisiopatología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Ratones Transgénicos , Placa Motora/fisiopatología , Contracción Muscular/genética , Contracción Muscular/fisiología , Mutación Missense , Osteocondrodisplasias/fisiopatología , Fenotipo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...